Grace Park
Family · Federal Way, WANPI 1811363195
Payments from drug & device makers
Across 106 payments — averaging $21.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$425
- Boehringer Ingelheim$256
- AstraZeneca$176
- Novo Nordisk$156
- Amgen$128
- Lilly USA, LLC$128
- plus $1K from 19 others
What the payments were for
- Food & beverage$2,272100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 20 | $425 |
| Boehringer Ingelheim | 13 | $256 |
| AstraZeneca | 10 | $176 |
| Novo Nordisk | 8 | $156 |
| Amgen | 5 | $128 |
| Lilly USA, LLC | 6 | $128 |
| Shield Therapeutics Inc | 5 | $123 |
| GSK | 6 | $123 |
| Bayer | 4 | $89 |
| Pfizer | 3 | $87 |
| Sumitomo Pharma America, Inc. | 3 | $78 |
| Otsuka America Pharmaceutical, Inc. | 3 | $73 |
| Xeris Pharmaceuticals, Inc. | 3 | $67 |
| Johnson & Johnson | 3 | $58 |
| Exact Sciences | 2 | $43 |
| Kowa Pharmaceuticals America, Inc. | 2 | $37 |
| Abbott | 2 | $34 |
| Corcept Therapeutics | 1 | $33 |
| Aimmune Therapeutics, Inc. | 1 | $30 |
| Dexcom, Inc. | 1 | $30 |
| IBSA Pharma Inc. | 1 | $24 |
| Mylan Specialty L.p. | 1 | $22 |
| Lundbeck LLC | 1 | $22 |
| Phathom Pharmaceuticals, Inc. | 1 | $17 |
| Astellas Pharma US Inc | 1 | $14 |
How this compares
$2,272 in reported general payments places this provider in the 90th percentile of 1,706 family providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 240 | $222,723 |
| JanuviaSitagliptin Phosphate | 162 | $154,711 |
| CreonLipase/Protease/Amylase | 116 | $154,360 |
| ProliaDenosumab | 32 | $56,179 |
| LinzessLinaclotide | 45 | $39,507 |
| EliquisApixaban | 36 | $38,760 |
| VascepaIcosapent Ethyl | 76 | $26,808 |
| RybelsusSemaglutide | 14 | $24,927 |
| MyrbetriqMirabegron | 36 | $23,769 |
| OzempicSemaglutide | 18 | $20,321 |
| TrulicityDulaglutide | 14 | $14,329 |
| Lidocaine | 99 | $12,771 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 15 | $12,421 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 16 | $10,458 |
| XareltoRivaroxaban | 15 | $8,622 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $256 | $222,723240 claims |
| AbbVieCreon, Linzess | $425 | $193,867161 claims |
| AmgenProlia | $128 | $56,17932 claims |
| Novo NordiskRybelsus, Ozempic | $156 | $45,24832 claims |
| PfizerEliquis | $87 | $38,76036 claims |
| Astellas Pharma US IncMyrbetriq | $14 | $23,76936 claims |
| GSKTrelegy Ellipta, Shingrix | $123 | $16,46844 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $176 | $14,90127 claims |
| Lilly USA, LLCTrulicity | $128 | $14,32914 claims |
| Johnson & JohnsonXarelto | $58 | $8,62215 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,706 family providers in Washington.
Other family in Federal Way
- Manaye UtaileFederal Way$7K
- Tawnie SteigerFederal Way$7K
- Lachelle DrollmanFederal Way$6K
- Patric SchineCentralia$842K
- Sharla PetersonKenmore$192K
- Zelda SwainSpokane$83K
- Savannah MorganRenton$76K
- Kevan PettersonSeattle$56K
- Kelly McFeeSunnyside$42K
- Cheryl SomersSpokane$31K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.